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situations makes it essential that all surgeons be familiar with 
this excellent technique. 
McLoughlin MG. Williams GM: J Urol 114:527. 1978. Schweizer 
RT. Bartus SA. Khan CS: J UroII17:12S. 1977. and Karmi SA. 
Dager Fl. Ranos E. Young 10 lr: Urology 11:380, 1978 
The above three papers are included to make the reader aware 
of the many and varied causes of late ureteric obstruction. Late 
perirenal lymphocele, rejection fibrosis. and obstruction caused 
by the spermatic cord are the factors described. 
Castro IE. Mustapha N. Mee AD, Shackman R: Br I UroI47:603. 
1975, and Lenitt SB, Caberwal D, Kogan SI. Ronas NA, Hardy 
MA: Urology 13:377. 1979 
OVERVIEW: 
These two papers stress that in the presence of uncorrectable 
abnormalities of the lower urinary tract. it is feasible and 
compatible Yoith long-term graft function to divert the urine into 
an intestinal conduit or a pre-existing cutaneous ureterostomy. 
Lucas BA. McRoberts JW. Curtis 11. Luke RG: I Urol 121:156. 1979 
These authors describe two techniques of ureteroneocystostomy. 
one of which provides an antireflux mechanism. However. 
although the importance of reftux in long-term graft failure 
remains unconfinned. it is desirable. where possible. to employ 
a technique or ureteroneocystostomy that will. in the majority of 
patients. prevent reftux. 
NEW PROCEDURES IN RENAL 
TRANSPLANTATION: IMPROVED 
QUALITY OF LIFE 
Richard Weil III and Thomas E. Starzl 
The articles in Chapters 12 to 15 were originally published 
between 1971 and 1979. The most recent of the four (Chapter 
12, published in 1979) summarizes the state of the field at that 
time; the other three articles describe technical aspects of 
bilateral nephrectomy in transplant recipients, donor nephrec-
tomy in living related kidney donors, donor nephrectomy in 
cadaver kidney donors, and ureterovesical anastomosis with 
intravesical and extravesical approaches. 
These clinical and technical articles are useful for urolo-
gists and for all surgeons who do kidney transplants. The four 
commentaries, with annotated bibliographies, provide mean-
ingful perspective on the four primary subjects. Although our 
practices in Denver vary from those of the authors in a number 
of details (e.g., we do not require pretransplant coronary 
angiography for all patients of a certain age, we do recipient 
nephrectomies through an anterior and usually transperitoneal 
approach, we have usually done pretransplant splenectomy for 
leukopenia associated with hypersplenism, and we remove 
cadaver donor kidneys with single vessels individually rather 
than en bloc). we nevertheless regard the principles and the 
methods described in the preceding articles and commentaries 
as sound and effective. 
During the last 2 years, surgeons performing clinical 
kidney transplantation. for the first time in more than \0 years 
have begun to realize the possibility of improving the quality 
of patient service, which has been long awaited but equally 
long delayed by lack of improvement in immunosl 
Until very recently, the basic tools of immunosuppression have 
been those defined in the early and middle 19608, in Denver 
as well as elsewhere: corticosteroids. azathioprine. and some-
times an antilymphocyte (ALG) or antithymocyte (ATG) 
globulin. I In the United States, for many years the I-year 
function of first cadaver kidney grafts has been essentially 
fixed at approximately the 50% mark in most centers, even 
with the use of A ro, although a few institutions with especially 
potent globulins have been able to exceed this unsatisfactory 
record. 2-5 A quantum improvement in the result of kidney 
transplantation, particularly cadaver kidney transplantation, 
has been made to wait for improvements in the immunosup-
pressive tools, so that better graft survival could be achieved 
without increased risk of mortality. 6 
Successful kidney transplantation, for most patients. offers 
a better quality of life than chronic hemodialysis. A minority 
of patients have a living relative who can donate a kidney for 
transplantation; therefore, any real upgrading of the service 
offered by kidney transplantation must have as its centerpiece 
improved graft and patient survival in cadaver kidney trans-
plantation. 
Supported by research projects from the Veterans Administration; 
by United States Public Health Service Grants AM-1726O and AM-
07772; and by Grants RR-00051 and RR-00069 fro'm the General 
Clinical Research Centers Program of the Division of Research 
Resources. National Institutes of Health. 
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There are now on the horizon at least five areas of applied 
immunology that are likely to have strong impact on kidney 
transplantation and, singly or in combination, to enable ca-
daver kidney homotransplantation with a high probability of 
success and a low probability of debilitatin~ side-effects. 
HISTOCOMPATIBILITY TESTING 
For 15 years, since the introduction of clinical histocompati-
bility testing, it has been hoped that this tool would make it 
possible to provide each kidney transplant recipient with a well 
enough matched graft that only small amounts of immunosup-
pressive agents would be needed to achieve satisfactory kidney 
function. However, in the United States the HLA matching 
system has been disappointing in its ability to predict outcome 
after cadaver transplantation. 
In a recent large survey of more than 100 North American 
transplant centers with data on 6226 primary cadaver kidney 
transplants, the I-year kidney graft function was 51%, with 
0-1 mismatched HLA antigens and 43% with 4 mismatched 
HLA antigens. 7 This small (8%) difference, and only a 51 % 
success rate with well-matched kidneys, illustrates the ex-
tremely limited value of HLA matching in a highly outbred 
population that depends on azathioprine and corticosteroids as 
the main immunosuppressive agents. 
It is possible that a relatively newly defined HLA locus, 
the HLA-DR locus, may prove to correlate more closely with 
cadaver graft outcome than the longer established HLA-A and 
HLA-B loci. The HLA-DR locus is thought to reflect cellular 
immunity more than humoral immunity, and the HLA-DR 
matching could therefore is expected to reflect cellular immune 
differences between kidney recipient and donor. Preliminary 
data indicate that there is some correlation between matching 
at least one HLA-DR antigen and cadaver transplant function; 
however, more experience with this method is necessary before 
any broad conclusions about its efficacy can be drawn. 8 
Improvements in the characterization of cytotoxic anti-
bodies have made possible more accurate direct crossmatching 
between recipient and donor with identification of false-positive 
res~lts. Ayoub and colleagues have demonstrated that recipient 
II;"II-B-lymphocyte antibodies will not cause hyperacute rejec-
tIons and do not contraindicate transplantation even when 
specifically directed against donor B-lymphocyte antigens.' 
The presence of cold anti-B-Iymphocyte antibodies before 
transplantation has, in fact, been associated with a more 
favorable prognosis than the absence of cytotoxic antibodies. 10 
These-cold anti-B-lymphocyte antibodies appear to be enhanc-
ing antibodies, and their induction may, in the future, become 
a method for preconditioning recipients in order to increase 
the probability of successful transplantation. 
BLOOD TRANSFUSIONS 
Opelz and Terasaki have demonstrated in a large retrospective 
study of 1852 patients that increasing numbers of packed red 
blood cell (RBC) transfusions, given before transplantation, 
increase first cadaver kidney survival at I year; with no 
transfusions the I-year graft function was 41%, whereas with 
more than 20 transfusions, it was 75%.11 The risk of this 
method, however, is that elective blood transfusions may, in 
some patients, produce such high titers of cytotoxic antibodies 
that transplantation for those individuals may no longer be 
possible. Salvatierra and associates recently transfused 45 
candidates with I-haplotype-identical related kidney donors' 
each recipient received 3 infusions of 250 ml of blood fro~ 
that individual's prospective related donor in preparation for 
related transplantation. Thirteen (29%) of these 45 patients 
-developed such high titers of cytotoxic antibodies that related 
transplantation was no longer considered safe and was not 
carried out. Of the 30 patients who did receive related grafts 
after the transfusions, 29 had excellent results. 12 Elective blOOd 
transfusion is therefore capable of improving the results of 
transplantation, but this improvement may also decrease the 
probability of successful transplantation in those individUals 
who develop cytotoxic antibodies in response to the transfu-
sions. 
TOTAL LYMPHOID IRRADIATION 
Pretransplantation total lymphoid irradiation (TLI) was shown 
?y Slavin and ~oll~gues to provide effective and specific 
immunosuppreSSIOn 10 rats. This central lymphoid irradiation 
is delivered through ports that are similar in design to the 
radiotherapy sometimes given for Hodgkin's disease and is 
safer than total body irradiation (TBI). In the rats, using 
pretransplantation TLI combined with infusions of donor bone 
marrow, Slavin and co-workers induced acceptance of heart 
and skin homografts from the animal that had donated the bone 
marrow, without ablating the recipient animal's ability to 
respond immunologically to grafts from third-party donorsY 
This form of pretreatment is currently being evaluated in 
patients at the University of Minnesota. • 
THORACIC DUCT DRAINAGE 
The fo~rth recent direction in applied immunology for trans-
plantatIon, thoracic duct drainage, is an approach that was 
~band~ned by most o! the centers that had previously employed 
it untIl a new technique, with a double lumen catheter and 
heparin instillation, was described in 1978 by Machleder and 
Paulus of the University of California at Los Angeles (UCLA). 10 
The procedure had previously been technically unreliable in a 
majority of patients. In 1978, in Denver, Koep and associates 
developed a modification of the UCLA thoracic duct drainage 
~thod,l~ which has permitted effective thoracic duct drainage 
10 mor~ than 90% of patients, including small children. Sixty-
five pnmary cadaver kidney transplant recipients received 
thoracic duct drainage between April 1978 and December 1979 
wi0 follow-up study of 6-26 months to date. Twenty-fiv~ 
patients began their thoracic duct drainage at the time of 
transplantation, 18 patients had thoracic duct drainage pretreat-
ment for fewer than 28 days before transplantation, and 22 
patients had thoracic duct drainage pretreatment for 28 or more 
days before transplantation. The results in these cases have 
been reported, and continuing follow-up has confirmed our 
impression that at least 28 days of thoracic duct drainage 
• Najarian JS: Personal communication. 
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pretreatment are necessary for the procedure to have maximum 
benefit. 16 The actuarial I-year patient survival in the group of 
patients who received at least 28 days of thoracic duct drainage 
pretreatment is 82%, and the actuarial I-year cadaver-graft 
survival is 73%. 
Although thoracic duct drainage is safe and effective if 
carried out for at least 28 days before, as well as for a short 
time after, transplantation, the procedure requires an additional 
operation and an additional period of hospitalization. During 
the last 6 months we in Denver have therefore been working 
with a new pharmacologic agent in an effort to provide improved 
patient service without the necessity for additional hospitali-
zation or operation. 
CYClOSPORIN A 
Cyclosporin A, a polypeptide, is extracted from a fungus by 
the Sandoz Company of Basel, Switzerland. The initial clinical 
trials were carried out by Calne and colleagues at Cambridge, 
England}' In Denver, during the last 6 months, 36 patients 
received cadaver kidney transplants with Cyclosporin A im-
munosuppression. All these patients also received corticoste-
roids, but in smaller amounts than in the past, when azathioprine 
and prednisone were the immunosuppressive agents. Eleven 
of the patients received thoracic duct drainage as well as 
Cyclosporin A and corticosteroids; 25 patients were treated 
with Cyclosporin A and corticosteroids without thoracic duct 
drainage. Two of those 36 patients have died: 1 of pneumonia, 
and one of hemorrhage after coronary artery bypass, 6 weeks 
after transplantation, with a normal kidney transplant. Two 
kidneys have been rejected. Not all the kidney transplants are 
functioning normally, but 32 of the 36 patients (89%) currently 
have transplants that can sustain life without dialysis. We are 
optimistic about the long-term effectiveness of Cyclosporin A 
as an immunosuppressant for transplantation. IS 
The 17 V2 years since the first kidney homograft was done 
in Denver have been characterized by short periods of appli-
cation of new technologies to improve results, followed by 
longer periods of consolidation of gains. During the 1970s, 
the main obstacle to providing patients with better transplan-
tation undoubtedly was unsatisfactory immunosuppression. 
In the 198Qs, the development of more effective and less 
toxic immunosuppression appears more probable than at any 
previous time. This probability carries with it the hope that 
kidney transplant patients, including those without living-
related donors, will be able to look forward to long lives that 
are not threatened by the morbid side effects of corticosteroids. 
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